Outcome in adult low-grade glioma: the impact of prognostic factors and treatment.
Low-grade gliomas (LGGs) represent a vexing clinical problem. Some patients present with readily controllable seizures and will enjoy years of freedom from tumor progression without intervention, whereas others progress rapidly with eventual neurologic decompensation and death. Both radiation and chemotherapy are helpful to many patients, but the optimal timing and sequencing of these therapies remain unknown. Recent studies have informed our understanding of clinical, histologic, and molecular prognostic factors and help provide guidance as to which patients require early intervention and when observation is feasible or warranted. We review contemporary knowledge regarding prognostic factors, our current evidence-based understanding of the roles and timing of radiation and chemotherapy, and ongoing clinical trials that will further elucidate management of LGGs.
Schiff
David
D
Neuro-Oncology Center, University of Virginia Health Sciences Center, Box 800432, Charlottesville, VA 22908-0432, USA. ds4jd@virginia.edu
Brown
Paul D
PD
Giannini
Caterina
C
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D002986:Clinical Trials as Topic / Q000592:standards; D018450:Disease Progression; D005910:Glioma / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000628:therapy; D011379:Prognosis; D011878:Radiotherapy / Q000592:standards / Q000639:trends
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor